JP2020534012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534012A5 JP2020534012A5 JP2020516576A JP2020516576A JP2020534012A5 JP 2020534012 A5 JP2020534012 A5 JP 2020534012A5 JP 2020516576 A JP2020516576 A JP 2020516576A JP 2020516576 A JP2020516576 A JP 2020516576A JP 2020534012 A5 JP2020534012 A5 JP 2020534012A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- kappa light
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 230000027455 binding Effects 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017102631 | 2017-09-21 | ||
| CNPCT/CN2017/102631 | 2017-09-21 | ||
| PCT/CN2018/106619 WO2019057100A1 (en) | 2017-09-21 | 2018-09-20 | NEW ANTI-CD19 ANTIBODIES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534012A JP2020534012A (ja) | 2020-11-26 |
| JP2020534012A5 true JP2020534012A5 (enExample) | 2021-10-28 |
| JP7295098B2 JP7295098B2 (ja) | 2023-06-20 |
Family
ID=65810659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516576A Active JP7295098B2 (ja) | 2017-09-21 | 2018-09-20 | 新規抗ｃｄ１９抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11497769B2 (enExample) |
| EP (1) | EP3684820A4 (enExample) |
| JP (1) | JP7295098B2 (enExample) |
| KR (2) | KR102782109B1 (enExample) |
| CN (2) | CN109535253B (enExample) |
| AU (2) | AU2018336520B2 (enExample) |
| BR (1) | BR112020005402A2 (enExample) |
| CA (1) | CA3074524A1 (enExample) |
| IL (2) | IL273389B2 (enExample) |
| MX (2) | MX2020003093A (enExample) |
| SG (1) | SG11202001817PA (enExample) |
| TW (3) | TW202417507A (enExample) |
| WO (1) | WO2019057100A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| CN110003334B (zh) * | 2019-04-12 | 2023-05-09 | 深圳普瑞金生物药业股份有限公司 | 多肽、cd19单域抗体及其制备方法、核苷酸序列及试剂盒 |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| CN111303287B (zh) * | 2019-12-05 | 2022-05-20 | 常州费洛斯药业科技有限公司 | 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用 |
| CN110922482B (zh) * | 2019-12-25 | 2021-08-31 | 源道隆（苏州）医学科技有限公司 | 可结合cd19的多肽及其应用 |
| BR112022021450A2 (pt) | 2020-04-24 | 2022-12-27 | Millennium Pharm Inc | O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada |
| CN111840571B (zh) * | 2020-08-03 | 2022-09-20 | 杭州皓阳生物技术有限公司 | 一种抗体药物偶联物及其用途 |
| WO2022266075A1 (en) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain |
| EP4368640A4 (en) * | 2021-07-09 | 2025-01-22 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Cd19 antibody and application thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| EP1648512A4 (en) * | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| CN101233156B (zh) * | 2005-06-20 | 2012-06-27 | 米德列斯公司 | Cd19抗体及其用途 |
| ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| CN103694349A (zh) * | 2006-09-08 | 2014-04-02 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| CL2007003622A1 (es) * | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| CN101903403B (zh) * | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| WO2010095031A2 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| EP2409993A1 (en) * | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| WO2014065402A1 (ja) * | 2012-10-26 | 2014-05-01 | 株式会社ペルセウスプロテオミクス | 抗ヒトｃｄ４０モノクローナル抗体及びその利用 |
| PL2900277T3 (pl) * | 2012-12-13 | 2022-05-16 | Immunomedics, Inc. | Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności |
| US9758575B2 (en) * | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
| CN108137698B (zh) | 2015-10-02 | 2022-04-19 | 豪夫迈·罗氏有限公司 | 抗人cd19抗体 |
| EP3478722A1 (en) | 2016-06-30 | 2019-05-08 | F. Hoffmann-La Roche AG | Improved adoptive t-cell therapy |
| AU2019282836B2 (en) | 2018-06-07 | 2025-09-04 | Cullinan Oncology, Inc. | Multi-specific binding proteins and methods of use thereof |
-
2018
- 2018-09-20 KR KR1020207011014A patent/KR102782109B1/ko active Active
- 2018-09-20 KR KR1020257008083A patent/KR20250042189A/ko active Pending
- 2018-09-20 IL IL273389A patent/IL273389B2/en unknown
- 2018-09-20 IL IL317928A patent/IL317928A/en unknown
- 2018-09-20 WO PCT/CN2018/106619 patent/WO2019057100A1/en not_active Ceased
- 2018-09-20 JP JP2020516576A patent/JP7295098B2/ja active Active
- 2018-09-20 SG SG11202001817PA patent/SG11202001817PA/en unknown
- 2018-09-20 TW TW112133526A patent/TW202417507A/zh unknown
- 2018-09-20 TW TW107133196A patent/TWI812645B/zh active
- 2018-09-20 CN CN201811100667.3A patent/CN109535253B/zh active Active
- 2018-09-20 TW TW113133341A patent/TWI878186B/zh active
- 2018-09-20 CN CN202211276301.8A patent/CN115819588A/zh active Pending
- 2018-09-20 US US16/649,157 patent/US11497769B2/en active Active
- 2018-09-20 EP EP18858685.3A patent/EP3684820A4/en active Pending
- 2018-09-20 BR BR112020005402-0A patent/BR112020005402A2/pt unknown
- 2018-09-20 MX MX2020003093A patent/MX2020003093A/es unknown
- 2018-09-20 CA CA3074524A patent/CA3074524A1/en active Pending
- 2018-09-20 AU AU2018336520A patent/AU2018336520B2/en active Active
-
2020
- 2020-03-19 MX MX2025009320A patent/MX2025009320A/es unknown
-
2025
- 2025-04-23 AU AU2025202830A patent/AU2025202830A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534012A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP7257971B2 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2020510422A5 (enExample) | ||
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| JP2020513791A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2018532383A5 (enExample) | ||
| JP2012523848A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2009518039A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| RU2012112340A (ru) | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью | |
| JP2020534830A5 (enExample) | ||
| JP2019523651A (ja) | 抗ｐｓｍａ抗体およびその使用 | |
| JP2019523651A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2021510533A (ja) | 抗４−１ｂｂ抗体、その抗原結合フラグメント、およびその医学的使用 | |
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JP2019512207A5 (enExample) | ||
| IL273389B1 (en) | New anti-CD19 antibodies | |
| JP7512413B2 (ja) | 抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途 | |
| JP2024001073A5 (enExample) | ||
| JP2014515600A5 (enExample) | ||
| JP2023537958A (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 |